Early-stage biotechnology company Virios Therapeutics, Inc. announced plans to use IMC-2 (a combination of valacyclovir and celecoxib) to treat fatigue, orthostatic intolerance and other symptoms of LC (also known as post-acute). Consequences of...
AstraZeneca Pharma India Ltd has announced that it has received approval from the Indian Standard Drugs Control Organization (CDSCO) to import and market Andexanet Alfa. FXa inhibitors are used to prevent and treat thrombotic events such as deep...
The Indian government should allocate more funds for research and development, health funds and drug innovations in the health sector, industry experts expect in the 2024 budget
Wipro GE Healthcare, global healthcare technology specialist, developer and provider of digital solutions, has signed a memorandum of understanding (MOU) with India's premier research institute.
The U.S. health regulator said on Monday companies will be required to add a serious warning on the prescribing information for cancer therapies known as CAR-T, made by Gilead Sciences, Johnson & Johnson, Novartis and others.
Curasight A/S (Curasight), a global leader in radiology, announced that it has achieved the first milestone in the development of Curasight's uTRACE PET imaging technology for the treatment of prostate cancer through an agreement with Curium Inc
Galderma, an emerging leader in the pure-play dermatology category, announced that it has received approval from Health Canada for Restylane Shaype, an injectable hyaluronic acid (HA) solution for temporary augmentation of the chin area. Restylane...
Ionis Pharmaceuticals said the drug to treat this rare genetic disease met the primary goal of a late-stage study. The drug donidalorsene reduced the number of seizures in patients with hereditary angioedema better than placebo. They were treated...
Pioneering clinical-stage biotechnology company Sensorion announces that it has received approval for its Clinical Trial Application (CTA) to initiate a Phase 1/2 clinical trial of SENS-501 (OTOF-GT) in France. The conclusion of Part I of the...
Sandoz, a key producer of generics and biosimilars, announced that it has signed an agreement to acquire US biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc. For $170 million in cash. According to the company’s...
, CDSCO.jpg)
